Hamid, Karachi Sanjiv Mahadeva, Kuala Lumpur Satawat Thongsawat, Chiang Mai Sathaporn Manatsathit, Bangkok Shiv Kumar Sarin, New Delhi Shomei Ryozawa, Yokohama Siam Sirinthornpanya, Bangkok Siew C Ng, Hong Kong Siriboon Attasaran, Bangkok Siriluck Papasivorakul, Bangkok Siwaporn Chainuvati, Bangkok Somchai Leelakusolvong, Bangkok Somying Tumwasorn, Bangkok Soon Koo Baik, Wonju Subrat click here S. K. Acharya, New Delhi Supot Pongprasobchai, Bangkok Supreecha Asavakarn, Bangkok Suthep
Gonchanvit, Bangkok Takao Itoi, Tokyo Takeshi Azuma, Kobe Taned Chitapanarux, Bangkok Tanittha Chatsuwan, Bangkok Tawesak Tanwandee, Bangkok Taya Kitiyakara, Bangkok Teerha Piratvisuth, Bangkok Thawatchai Akaraviputh, Bangkok Theranand Sanpajit, Bangkok Tsang Bih Shiou Charles, Singapore Tsutomu Chiba, Kyoto Uday C Ghoshal, Lucknow Uthai Khow-ean, Songkla Varocha Mahachai, Bangkok Varut Lohsiriwat,
Bangkok Vincent Wong, Hong Kong Voranush Chongsrisawat, Bangkok Wanich Piyaniran, Bangkok Wan-Long Chuang, Kaohsiung Worabuth Taweerutchana, Bangkok Yasushi Sano, Kobe Yi-You Chiou, Taipei Yogesh K. Chawla, Chandigarh Yutaka Saito, Kyoto “
“I read the very interesting article by Finn1 about sorafenib, the first systemic agent showing a survival advantage when it is used to treat patients with hepatocellular carcinoma. Finn1 pointed out common and predictable toxicities, including hand-skin reactions, anorexia, and diarrhea, which were experienced Y-27632 mouse by 15% to 40% of the treated patients.
However, Finn1 did not mention the importance of health-related quality of life (HRQOL) with respect to the potential side effects of hepatocellular carcinoma treatment and wrote only a few words about the cost of the drug. The growth of health care costs continues to outpace our ability to pay for health care in the future. We need to know not only the clinical efficacy of the drug but also its cost-effectiveness and the HRQOL of patients randomized see more between a placebo and sorafenib. Studies of HRQOL may add value in a variety of ways, including the provision of data that may contrast with or support the primary outcome and sometimes change a study’s interpretation. Studies of cost-effectiveness and HRQOL may provide valuable sources of additional information useful to both the clinician and the patient when treatment decisions are being made, and they are considered important endpoints together with traditional measures.2 I think that their assessment is particularly worthwhile for trials in which survival rates are low. Natalia Terreni M.D.*, Giancarlo Spinzi M.D.*, * Division of Gastroenterology, Valduce Hospital, Como, Italy. “
“Cheung J, Soo I, Bastiampillai R, Zhu Q, Ma M. Urgent vs.